Tome Bioscience

Tome Biosciences is a genome-editing therapeutics company founded in 2021 and based in Watertown, Massachusetts. It develops programmable genomic integration (PGI) technology that pairs the site-specificity of CRISPR/Cas with integrase enzymes to insert genetic sequences of virtually any size into the genome without relying on double-strand DNA breaks. The company was cofounded by Omar Abudayyeh and Jonathan Gootenberg, formerly of MIT's McGovern Institute, and raised roughly $213M across Series A and B financing led in part by a16z. Its stated programs target integrative gene therapies for monogenic liver diseases and cell therapies for autoimmune conditions. Tome is a biopharmaceutical R&D company with no public API, developer portal, SDKs, or machine-readable API surface; its documented website (tome.bio) does not currently resolve. It is tracked in the API Evangelist network as an a16z portfolio company / enrichment lead rather than an API producer.

Tome Bioscience is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Genome Editing, Gene Therapy, and CRISPR.

🌐 Visit website 📡 Source on GitHub

5.7/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-07-27 · rubric v0.5

0 APIs

CompanyBiotechnologyGenome EditingGene TherapyCRISPRLife SciencesTherapeutics

Kin Score

Kin Score How this is scored →
scored 2026-07-27 · rubric v0.5

Composite quality — 5.7/100 · minimal

Contract Quality 0.0 / 25

Developer Ergonomics 0.0 / 20

Commercial Clarity 0.0 / 20

Operational Transparency 0.0 / 13

Governance 0.0 / 12

Discoverability 6.8 / 10

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 15

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/tome-bioscience: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Source (apis.yml)

aid: tome-bioscience
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/tome-bioscience.png
name: Tome Bioscience
description: Tome Biosciences is a genome-editing therapeutics company founded in 2021 and based in Watertown, Massachusetts.
  It develops programmable genomic integration (PGI) technology that pairs the site-specificity of CRISPR/Cas with integrase
  enzymes to insert genetic sequences of virtually any size into the genome without relying on double-strand DNA breaks. The
  company was cofounded by Omar Abudayyeh and Jonathan Gootenberg, formerly of MIT's McGovern Institute, and raised roughly
  $213M across Series A and B financing led in part by a16z. Its stated programs target integrative gene therapies for monogenic
  liver diseases and cell therapies for autoimmune conditions. Tome is a biopharmaceutical R&D company with no public API,
  developer portal, SDKs, or machine-readable API surface; its documented website (tome.bio) does not currently resolve. It
  is tracked in the API Evangelist network as an a16z portfolio company / enrichment lead rather than an API producer.
url: https://raw.githubusercontent.com/api-evangelist/tome-bioscience/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- a16z
x-tier: stub
x-tier-reason: portfolio-lead
x-industry: Biotechnology
x-headquarters: Watertown, Massachusetts, USA
x-founded: '2021'
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-21'
tags:
- Company
- Biotechnology
- Genome Editing
- Gene Therapy
- CRISPR
- Life Sciences
- Therapeutics
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
x-enrichment:
  date: '2026-07-21'
  status: nochange
  artifacts_added: 0
  pass: local-v1